April 23, 2021
Business News

Take Advantage of Vaxart’s Sharp Pullback, Says Analyst

The recent news of an adverse reaction suffered by a participant in AstraZeneca’s Covid-19 vaccine candidate’s clinical trial demonstrated that getting an approved vaccine to market is no straight forward matter. What the unfortunate event also shows, is that the race to be first across the finish line with a viable solution is far from over.

The field is still open, then, for vaccine specialist Vaxart (Click here to view the original article.

Related Posts

You might also like ...

JAB Welcomes Lubomira Rochet as Partner
Cognizant Achieves Guidewire PartnerConnect Cloud Specialization
Netsmart and Vermont Collaborative Launch Care Coordination Platform to Deliver on Data-Driven, Value-Based Care